Sisram Med Trading Debut on SEHK on 19 September 2017

Net Proceeds of approximately HK$877.2 Million from Global Offering

HONG KONG, Sept. 20, 2017 /PRNewswire/ -- Sisram Medical Ltd ("Sisram Med" or the "Company"; stock code: 1696.HK), announced the allotment results of its global offering, which offers a total of 110,000,000 shares comprising of 88,000,000 new shares offered by the Company and 22,000,000 sale shares by a controlling shareholder, Magnificent View Investments Limited (the "Selling Shareholder" ). The offer price was set at HK$8.88 per share. Assuming that the over-allotment option is not exercised, the net proceeds from the global offering to be received by the Company, after deduction of underwriting fees and commissions and estimated expenses payable in connection with the global offering, are estimated to be approximately HK$688.7 million; while those to be received by the Selling Shareholder, after deduction of underwriting fees and commissions payable, are estimated to be approximately HK$188.5 million.

The valid applications received pursuant to the Hong Kong public offering represented approximately 17.58 times of the total number of 11,000,000 Hong Kong offer shares initially available for subscription. Due to the over-subscription, a total number of 22,000,000 shares have been reallocated from the international offering to the Hong Kong public offering. As a result, a final number of 33,000,000 offer shares were allocated to the Hong Kong public offering, representing 30% of the global offering size before any exercise of the over-allotment option.

The international offering was also moderately over-subscribed.  After reallocation, a final number of 77,000,000 offer shares were allocated to the placees and qualifying shareholders of Fosun International Limited under international offering, including the reserved shares offered under the preferential offering.

Sisram Med has entered into cornerstone investment agreements with Shanghai Free Trade Zone Phase I Equity Investment Fund Partnership Enterprise (Limited Partnership), Rise Huge Corporation Limited and Neo Derm Group Limited for the subscription of aggregate 25,296,800 offer shares, with respective offer shares of 13,175,600 shares, 8,783,600 shares and 3,337,600 shares, accounting for approximately 23.00% of the global offering size before any exercise of the over-allotment option.

China International Capital Corporation Hong Kong Securities Limited ("CICC") and Jefferies Hong Kong Limited (in alphabetical order) are the joint sponsors, and together with Fosun Hani Securities Limited are the joint global coordinators. The joint global coordinators, together with Haitong International Securities Company Limited, Huatai Financial Holdings (Hong Kong) Limited and CMB International Capital Limited (in relation to the international offering only) are the joint bookrunners and joint lead managers. CICC is the sole settlement agent and sole stabilizing manager.                       

Share trading of Sisram Med on the Main Board of the Hong Kong Stock Exchange Limited ("SEHK") was commenced on 19 September 2017 (Tuesday), with the stock code 1696 in board lots of 400 shares each.

About Sisram Medical Ltd

Sisram Medical Ltd (stock code: 1696.HK) is a leading global provider of energy-based medical aesthetic treatment systems, with comprehensive in-house capability to design, develop and produce such systems, which often feature the Company's innovative and proprietary technologies. "Alma" brand, as well as the brands of many of the Company's products such as "Soprano", "Harmony", "Accent" and "FemiLift", are widely recognized and well regarded among treatment providers and treatment recipients internationally. The Company has also been the largest provider of energy-based medical aesthetic treatment systems in the PRC market and one of the leaders in the medical aesthetic treatment system market globally, in terms of revenue in 2016, according to the Medical Insight Report. The company sells its treatment systems in approximately 80 countries and jurisdictions worldwide. Sisram Med, incorporated in 2013 in Israel, is a non-wholly owned subsidiary of Fosun Pharma. Fosun Pharma is a leading healthcare group in China with businesses covering the whole healthcare industry chain.

Not for publication, distribution or release, directly or indirectly in or into the United States or any other jurisdiction in which such publication, distribution or release would be prohibited by applicable laws.

This press release does not constitute and is not an offer to sell or the solicitation of an offer to buy securities (the "Securities") of SISRAM MEDICAL LTD (the "Company") in the United States or elsewhere. The Company has not registered and does not intend to register the Securities under the US Securities Act of 1933, as amended (the "Securities Act"), and the Securities may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration under the Securities Act.  There will be no public offer of the Securities in the United States, Israel or any jurisdiction other than Hong Kong.